ViroPharma Incorporated - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for ViroPharma Incorporated. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

ViroPharma Incorporated. The Group's principal activity is to develop and commercialize products that address serious diseases treated by physician specialists, in areas including hospital settings, transplant medicine and gastroenterology. It is focused on the marketing and sale of its commercialized product, Vancocin, an oral capsule to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. The development activities are currently focused on product candidates to treat viral diseases including those caused by cytomegalovirus (CMV) and hepatitis C (HCV) infections. As on 21-Oct-2008, it acquired Lev Pharmaceuticals Inc.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report